June brought major breast cancer updates, and CURE is sharing the latest treatment combinations, biomarker-driven care and ...

Diagnosis and treatment of breast cancer can differ for patients in rural communities compared with those in urban ...

The official results of the BRACELET-01 (PrECOG 0113) trial have been published in Clinical Cancer Research, detailing the ...

For the first time in Australia, a drug that can delay the growth of tumours is available under the Pharmaceutical Benefits ...

A new medication found to reduce the chance of the most common types of breast cancer recurring will be available to many ...

Patients with certain subtypes of breast cancer may be at higher risk for death by waiting more than 42 days after their ...

Dr. Sara M. Tolaney breaks down key takeaways from the DESTINY-Breast09 trial that patients with HER2+ advanced or metastatic ...

Novartis Canada is pleased to announce that Health Canada has granted a Notice of Compliance (NOC) for KISQALI® (ribociclib ...

DelveInsight's HER2-low Cancers Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, emerging HER2-low ...

At the recent American Society of Clinical Oncology (ASCO) annual meeting, interim results from the DESTINY-Breast09 trial ...

Dr Mariana Chavez MacGregor highlights how updates from ASCO 2025 are already improving outcomes in her clinic.